Blocking circDPP4 antagonizes cell progression of PC and contributes to in vitro DTX cytotoxicity via regulating the miR-564/ZIC2 axis, at least. The present study suggests that circDPP4 is a potential biomarker and target for PC.
Silencing of circDPP4 suppresses cell progression of human prostate cancer and enhances docetaxel cytotoxicity through regulating the miR-564/ZIC2 axis.